1 Introduction Cardiovascular disease (CVD) continues to be a significant global health concern, with ischemic stroke and acute myocardial infarction ranking as the second and third leading causes of death worldwide in 2019 ( The complex interaction between diabetes mellitus (DM) and cardiovascular events complicates patient management
These are descriptive categories, not rigid classifications, but they help set expectations
Remember: sustainable weight loss is a journey, not a destination
Luo Q, Hou Y, Yin N, Zhang H
Semaglutide vs Tirzepatide: Key Differences at a Glance While both medications are highly effective, their differences can matter when tailoring treatment: Mechanism of action Semaglutide: GLP-1 receptor agonist Tirzepatide: Dual GLP-1 + GIP receptor agonist Average weight loss Semaglutide: Significant and consistent weight reduction Tirzepatide: Often produces greater total weight loss in clinical trials Metabolic effects Semaglutide: Strong appetite control and satiety Tirzepatide: Appetite control plus enhanced metabolic and insulin effects Side effect profile Both: Most commonly include nausea, constipation, diarrhea, or reflux, typically during dose escalation Neither option is better universally tolerability varies by individual How Do You Choose the Right GLP-1 for Weight Loss
Buy now, pay later plans are also available
